PPARA and cataract: Considering the broad action of PPARα agonists, the mechanism by which fenofibrate treatment potentially reduces cataract formation in the chmru848 embryos is not fully understood, but it may be through lowering cholesterol levels, which can cause cataracts when disturbed (40).